April 29, 2024
Grifols launches its Erytra Eflexis, a powerful blood-typing system, in China
- New solution marks another Grifols immunohematology milestone in China, where it has been ensuring the safety of the country’s blood supply for 25 years
- Erytra Eflexis is a fully automated, powerful analyzer that flexibly adapts to variable volumes to perform complex pretransfusion compatibility testing
- The rollout in China of the innovative blood-typing system greatly enhances Grifols’ leadership in transfusion medicine
Barcelona, Spain, April 29, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced it has launched its leading blood-typing technology – the fully automated Erytra Eflexis – in the Chinese market following regulatory approval.
The system, with “load-and-go” automation to rapidly perform complex blood-typing analytics, represents a new generation of fully automated blood typing analyzers designed to enhance pretransfusion compatibility testing.
Using Grifols' proprietary DG gel technology, which confirms blood-group compatibility through the presence or absence of different red-blood antigens and antibodies, the smart, flexible, and intuitive Erytra Eflexis optimizes workflow efficiency and improves daily workloads at hospitals’ immunohematology laboratories.
It can be tailored to various lab configurations and processing needs with a high level of flexibility and adaptability while providing reliable, timely results. It can also be employed as a standalone solution or in combination with other Grifols instrumentation.
The availability of Erytra Eflexis in China comes 25 years after Grifols introduced its first immunohematology systems in the country. It builds on the existing local portfolio that also includes Procleix automated NAT (nucleic acid test) solutions based on proprietary TMA (transcription-mediated amplification) technology for blood and plasma screening. The company, an established global leader in transfusion medicine, first began doing business in the country in 1983.
“We are committed to fostering localization and further strengthening China’s innovative diagnostics ecosystem to benefit patients,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “With the introduction of the highly flexible and efficient Erytra Eflexis in China, Grifols continues to reinforce its leadership in transfusion safety.”
About Grifols Erytra Eflexis
Erytra Eflexis is a state-of-the-art, mid-sized analyzer that performs pretransfusion compatibility testing. The system allows for high throughout and enables optimized staffing, reduced waste, improved patient care, as well as increased efficiency and accuracy.
About DG Gel System
The DG Gel system instruments and reagents use the DG Gel card technology to help labs streamline pretransfusion compatibility tests and tailor the extended phenotype profile for each patient's need. DG Gel system reagents include comprehensive DG Gel card profiles, reagent red blood cell options and complete liquid antisera.
To learn more, visit: https://www.diagnostic.grifols.com/en/dg-gel-system